Definium Therapeutics (DFTX) Shares Outstanding (2020 - 2026)

Definium Therapeutics (DFTX) has reported Shares Outstanding (Entity) for 7 consecutive years, with $104.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 37.79% year-over-year to $104.0 million; the TTM figure through Mar 2026 stood at $104.0 million (up 37.79% YoY), while the FY2025 annual figure was $98.8 million, up 31.52% from the prior year.
• Shares Outstanding (Entity) grew to $104.0 million in Q1 2026 per DFTX's latest filing, from $98.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $104.0 million in Q1 2026 and bottomed at $28.2 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $57.8 million across 5 years, with a median of $47.9 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 103.49% — and 2025, when it declined 5.9%.
• Definium Therapeutics' Shares Outstanding (Entity) stood at $30.9 million in 2022, then surged by 33.2% to $41.1 million in 2023, then jumped by 82.72% to $75.1 million in 2024, then jumped by 31.52% to $98.8 million in 2025, then rose by 5.33% to $104.0 million in 2026.
• Business Quant data shows DFTX's Shares Outstanding (Entity) at $104.0 million in Q1 2026, $98.8 million in Q4 2025, and $76.8 million in Q3 2025.